Cerebrovascular accidents in sickle cell disease: rates and risk factors
- PMID: 9414296
Cerebrovascular accidents in sickle cell disease: rates and risk factors
Abstract
Cerebrovascular accident (CVA) is a major complication of sickle cell disease. The incidence and mortality of and risk factors for CVA in sickle cell disease patients in the United States have been reported only in small patient samples. The Cooperative Study of Sickle Cell Disease collected clinical data on 4,082 sickle cell disease patients enrolled from 1978 to 1988. Patients were followed for an average of 5.2 +/- 2.0 years. Age-specific prevalence and incidence rates of CVA in patients with the common genotypes of sickle cell disease were determined, and the effects of hematologic and clinical events on the risk of CVA were analyzed. The highest rates of prevalence of CVA (4.01%) and incidence (0.61 per 100 patient-years) were in sickle cell anemia (SS) patients, but CVA occurred in all common genotypes. The incidence of infarctive CVA was lowest in SS patients 20 to 29 years of age and higher in children and older patients. Conversely, the incidence of hemorrhagic stroke in SS patients was highest among patients aged 20 to 29 years. Across all ages the mortality rate was 26% in the 2 weeks after hemorrhagic stroke. No deaths occurred after infarctive stroke. Risk factors for infarctive stroke included prior transient ischemic attack, low steady-state hemoglobin concentration and rate of and recent episode of acute chest syndrome, and elevated systolic blood pressure. Hemorrhagic stroke was associated with low steady-state hemoglobin and high leukocyte count.
Similar articles
-
The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.Blood. 1994 Jul 15;84(2):643-9. Blood. 1994. PMID: 7517723
-
Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.Blood. 1995 Jul 15;86(2):776-83. Blood. 1995. PMID: 7606007 Review.
-
Molecular characteristics of pediatric patients with sickle cell anemia and stroke.Am J Hematol. 2001 Jul;67(3):179-82. doi: 10.1002/ajh.1103. Am J Hematol. 2001. PMID: 11391715
-
Alpha thalassemia and stroke risk in sickle cell anemia.Am J Hematol. 1994 Apr;45(4):279-82. doi: 10.1002/ajh.2830450402. Am J Hematol. 1994. PMID: 8178798
-
Stroke prevention and treatment in sickle cell disease.Arch Neurol. 2001 Apr;58(4):565-8. doi: 10.1001/archneur.58.4.565. Arch Neurol. 2001. PMID: 11295986 Review.
Cited by
-
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.Am J Hematol. 2012 Oct;87(10):E65-8. doi: 10.1002/ajh.23278. Epub 2012 Jun 20. Am J Hematol. 2012. PMID: 22718523 Free PMC article.
-
Variability of Prognostic Results Based on Biological Parameters in Sickle Cell Disease Cohort Studies in Children: What Should Clinicians Know?Children (Basel). 2021 Feb 13;8(2):143. doi: 10.3390/children8020143. Children (Basel). 2021. PMID: 33668629 Free PMC article.
-
Role of age and neuroinflammation in the mechanism of cognitive deficits in sickle cell disease.Exp Biol Med (Maywood). 2021 Jan;246(1):106-120. doi: 10.1177/1535370220958011. Epub 2020 Sep 22. Exp Biol Med (Maywood). 2021. PMID: 32962408 Free PMC article.
-
Determining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data Sources.Am J Prev Med. 2016 Jul;51(1 Suppl 1):S24-30. doi: 10.1016/j.amepre.2016.02.011. Am J Prev Med. 2016. PMID: 27320461 Free PMC article.
-
Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):482-492. doi: 10.1182/asheducation-2018.1.482. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504349 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical